Newron secures €5.5M tranche in €38M push for schizophrenia drug trials
What's the deal? Newron Pharmaceuticals has raised €5.5 million through a second tranche of shares subscribed by the investor group backing its up to €38 million financing agreed in February 2026. The Milan-based biopharmaceutical company issued 433,070 new shares to fund its Phase 3 evenamide program.
Why now? The tranche strengthens Newron's balance sheet as it advances the ENIGMA-TRS 1 and 2 pivotal studies. The proceeds are meant to extend the company's cash runway beyond the trials' pivotal 12-week results.
What's the endgame? Newron is developing evenamide, a first-in-class glutamate modulator, as a potential add-on therapy for treatment-resistant schizophrenia and poorly responding patients. It would be the first such option in a field where safety profiles are often problematic.
How does the financing break down? The investor group initially subscribed to up to 779,624 shares at €19.24 each, for roughly €15 million. A third tranche of €5.5 million is due by November 30, 2026, with a further €12 million to follow if the ENIGMA-TRS studies return positive results.
The new shares will list on the SIX Swiss Exchange and on Germany's Düsseldorf and Frankfurt exchanges.
Endorsements matter. Newron already markets Xadago/safinamide for Parkinson's disease across markets including the EU, US, UK, and Japan. It has also signed evenamide development and commercialisation deals with EA PharmaDealroom has a profile for this one. Try Dealroom →, a subsidiary of EisaiDealroom has a profile for this one. Try Dealroom →, and South Korea's Myung In PharmDealroom has a profile for this one. Try Dealroom →.
The signal: Tying capital to clinical milestones lets a small-cap drug developer fund an expensive Phase 3 program without a single large dilution, while the staged structure signals investor conviction in evenamide's path to market.
Read more: globenewswire.com
Image credit: Generated with Gemini
